Pharma Industry Readies for Drug Pricing Lawsuit Second Wave

Major drug companies are likely to ratchet up a sprawling legal attack aimed at challenging the Biden administration’s Medicare drug pricing negotiation process, a top pharmaceutical lobby leader told Bloomberg Law.